Cell and gene therapy pipelines are increasing at a rapid pace thanks in large part to burgeoning manufacturing technologies.1 However, there are still many issues in the workflow and a strong need for standardization and controls to bring safe and effective cell and gene therapies to the market to help patients in need of these lifesaving treatments.